In the first half of 2022, Radicle Science will continue to conduct rigorous clinical trials on CBD products while also commencing on blinded, randomized, placebo-controlled clinical trials on rare cannabinoids.

Initial findings of the Radicle ACES (Advancing CBD Education and Science) study indicate a significant number of participants experienced clinically meaningful improvements.

The new Radicle Science-OBX alliance fills a need for rigorous scientific research in the cannabis industry and sets a new gold standard for CBD and minor cannabinoid product development.

Using a virtual, direct-to-consumer approach, Radicle ACES is the largest and most comprehensive randomized controlled trial of its kind, collecting data on 13 U.S. CBD brands.

Dr. Jeff Chen, founder of Radicle Science, presented his expertise on the scientific side of cannabis during Cannabis Products Exchange, held virtually April 27-28.

The study will use Radicle Science's Real World Evidence approach to better understand the impact of Prospect Farms' Dream Tincture when used nightly over the course of a month.